EASTERN COOPERATIVE ONCOLOGY GROUP

我们的计划非常适合参加临床试验 东部肿瘤协作组（Eastern Cooperative Oncology Group）。 的 罗切斯特大学癌症中心（URCC）是一个健康和 作为多医院联合体组织的研究所 涉及l个三级护理中心和4个全方位服务社区 医院的 它致力于临床和基础实验室 研究、病人护理和教育。 教师举行小学 在中心的学术任命，以及教学 大学临床或基础科学部门的任命。 它为120万人口提供服务。 我们的ECOG会员资格 已经发展到包括5个额外的表演场地， 外展社区医院（4家位于东北地区） 在加拿大的魁北克有一个卫星成员。 本ECOG支持的持续长期目标和具体目标 申请包括：l）参与多式联运第二阶段， III临床研究; 2）加速癌症治疗的进展 在成人患者中，通过增加累积; 3）增强基础- 科学与临床的相互作用; 4）进一步发展癌症控制 （5）广泛宣传 通过快速数据收集和出版物提供信息; 6） 保持质量和及时的数据管理，以及7）继续 履行本集团的行政职责。 多学科技术在日常癌症中的转移 实践设置不仅有利于那些进入 研究方案，也适用于接受 “标准”方法。 通过ECOG沟通、教育和 最佳治疗，我们希望能提供最先进的护理， 提高癌症患者的生存率和生活质量 患者

Our program is ideally suited to participate in the clinical trial activities of the Eastern Cooperative Oncology Group. The University of Rochester Cancer Center (URCC) is a health and research institute organized as a multihospital consortium involving l tertiary care center and 4 full-service community hospitals. It is committed to clinical and basic laboratory research, patient care, and education. The faculty hold primary academic appointments in the Center as well as a teaching appointment in a University clinical or basic science department. It serves a population of 1.2 million people. Our ECOG membership has grown to include 5 additional performance sites involving outreach community hospitals (4 located in the regional Northeast section of the country and l satellite member in Quebec, Canada. Continued long-term goals and specific aims supported by this ECOG application include: l) participation of multimodal Phase II and III clinical studies; 2) accelerate the advances of cancer therapy in adult patients through increased accrual; 3) enhance basic- science clinical interactions; 4) further develop cancer control and prevention initiatives; 5) provide wide dissemination of information through rapid data collection and publications; 6) maintenance of quality and timely data management and 7) continued service to the administrative responsibilities of the Group. The transfer of multidisciplinary technology in the daily cancer practice setting benefits not only the those patients entered onto research protocols, but also to cancer patients treated with "standard" approaches. Through ECOG communication, education, and optimal treatment, we can hopefully provide state-of-the-art care, increased survival and improved quality of life to our cancer patients.